Catalyst Biosciences - Stock Price History | CBIO

Historical daily share price chart and data for Catalyst Biosciences since 2021 adjusted for splits. The latest closing stock price for Catalyst Biosciences as of September 24, 2021 is 4.74.
  • The all-time high Catalyst Biosciences stock closing price was 176.91 on August 31, 2015.
  • The Catalyst Biosciences 52-week high stock price is 7.55, which is 59.3% above the current share price.
  • The Catalyst Biosciences 52-week low stock price is 3.72, which is 21.5% below the current share price.
  • The average Catalyst Biosciences stock price for the last 52 weeks is 5.20.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Catalyst Biosciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.8406 6.5000 8.5100 3.5000 6.3100 -7.34%
2019 7.4011 8.2500 10.6000 4.5200 6.8100 -13.69%
2018 17.1274 14.3700 35.6000 6.5900 7.8900 -42.16%
2017 5.8336 9.8876 15.0100 3.1900 13.6400 39.95%
2016 21.6539 46.0270 47.2264 8.0675 9.7466 -79.23%
2015 75.4001 133.1334 176.9115 29.9850 46.9265 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.153B $0.021B
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71